ContraFect Corp Sustainability Reports
A clinical-stage biotechnology company focused on discovering and developing direct lytic agents, such as bacteriophage-derived lysins, to treat life-threatening infectious diseases.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 549300JM7MIET5QG2X15
FIGI: BBG001V0GB00
3 reports from 2018 to 2021
